News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News October 28, 2025
Gibson Dunn Advised BVP Forge on Investment in Strategic Combination of Sunwave Health and Lightning Step
Gibson Dunn advised BVP Forge on its investment in the strategic combination of Sunwave Health and Lightning Step to form a unified technology platform, purpose-built for behavioral health providers nationwide
Firm News September 19, 2025
Gibson Dunn Advises 89bio on Its up to $3.5 Billion Sale to Roche Holdings
Gibson Dunn is advising 89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, on its up to $3.5 billion sale to Roche Holdings, Inc.
Firm News August 26, 2025
Gibson Dunn Advises Royalty Pharma on Acquisition of Royalty Interest in Amgen’s Imdelltra
Gibson Dunn is representing Royalty Pharma plc in its acquisition of a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for up to $950 million.
Firm News October 31, 2024
Gibson Dunn Advises Initial Purchasers on Garda World’s $1.0 billion Senior Notes Offering
Gibson Dunn represented Bank of America and the other initial purchasers on Garda World’s offering of $1.0 billion 8.375% senior notes due 2032.